Literature DB >> 22269088

The impact of direct aperture optimization on plan quality and efficiency in complex head and neck IMRT.

Marcello Sabatino1, Matthias Kretschmer, Klemens Zink, Florian Würschmidt.   

Abstract

BACKGROUND: Conventional step&shoot intensity modulated radio therapy (IMRT) approaches potentially lead to treatment plans with high numbers of segments and monitor units (MU) and, therefore, could be time consuming at the linear accelerator. Direct optimization methods are able to reduce the complexity without degrading the quality of the plan. The aim of this study is the evaluation of different IMRT approaches at standardized conditions for head and neck tumors.
METHOD: For 27 patients with carcinomas in the head and neck region a planning study with a 2-step-IMRT system (KonRad), a direct optimization system (Panther DAO) and a mixture of both approaches (MasterPlan DSS) was created. In order to avoid different prescription doses for boost volumes a simple standardization was realized. The dose was downscaled to 50 Gy to the planning target volume (PTV) which included the primary tumor as well as the bilateral lymphatic drainage (cervical and supraclavicular). Dose restrictions for the organs at risk (OAR) were downscaled to this prescription from high dose concepts up to 72 Gy. Those limits were defined as planning objectives while reaching definable PTV coverage with a standardized field setup. The parameters were evaluated from the corresponding dose volume histogram (DVH). Special attention was paid to the efficiency of the method, measured by means of calculated MU and required segments. Statistical tests of significance were applied to quantify the differences between the evaluated systems.
RESULTS: PTV coverage for all systems in terms of V90% and V95% fell short of the requested 100% and 95%, respectively, but were still acceptable (range: 98.7% to 99.1% and 94.2% to 94.7%). Overall for OAR sparing and the burden of healthy tissue with low doses no technique was superior for all evaluated parameters. Differences were found for the number of segments where the direct optimization systems generated less segments. Lowest average numbers of MU were 308 by Panther DAO calculated for 2 Gy fractions. Based on these findings the treatment time at the linear accelerator is the lowest for Panther DAO.
CONCLUSIONS: All IMRT approaches implemented in the different treatment planning systems (TPS) generated clinically acceptable and comparable plans. No superior system in terms of PTV coverage and OAR sparing was found. Major differences in efficiency of the method in terms of calculated MU and treatment times were found.

Entities:  

Mesh:

Year:  2012        PMID: 22269088      PMCID: PMC3275495          DOI: 10.1186/1748-717X-7-7

Source DB:  PubMed          Journal:  Radiat Oncol        ISSN: 1748-717X            Impact factor:   3.481


  17 in total

Review 1.  The physical basis of IMRT and inverse planning.

Authors:  S Webb
Journal:  Br J Radiol       Date:  2003-10       Impact factor: 3.039

2.  Direct aperture optimization: a turnkey solution for step-and-shoot IMRT.

Authors:  D M Shepard; M A Earl; X A Li; S Naqvi; C Yu
Journal:  Med Phys       Date:  2002-06       Impact factor: 4.071

3.  Three-dimensional conformal vs. intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters.

Authors:  Luca Cozzi; Antonella Fogliata; Alessandra Bolsi; Giorgia Nicolini; Jacques Bernier
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-02-01       Impact factor: 7.038

4.  Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT.

Authors:  Eugenio Vanetti; Alessandro Clivio; Giorgia Nicolini; Antonella Fogliata; Sarbani Ghosh-Laskar; Jai Prakash Agarwal; Ritu Raj Upreti; Ashwini Budrukkar; Vedang Murthy; Deepak Dattatray Deshpande; Shyam Kishore Shrivastava; Ketayun Ardeshir Dinshaw; Luca Cozzi
Journal:  Radiother Oncol       Date:  2009-01-20       Impact factor: 6.280

5.  Single Arc Volumetric Modulated Arc Therapy of head and neck cancer.

Authors:  Anders Bertelsen; Christian R Hansen; Jørgen Johansen; Carsten Brink
Journal:  Radiother Oncol       Date:  2010-02-24       Impact factor: 6.280

6.  Evaluation of surface and build-up region dose for intensity-modulated radiation therapy in head and neck cancer.

Authors:  Heeteak Chung; Hosang Jin; James F Dempsey; Chihray Liu; Jatinder Palta; Tae-Suk Suh; Siyong Kim
Journal:  Med Phys       Date:  2005-08       Impact factor: 4.071

7.  Rotational IMRT techniques compared to fixed gantry IMRT and tomotherapy: multi-institutional planning study for head-and-neck cases.

Authors:  Tilo Wiezorek; Tim Brachwitz; Dietmar Georg; Eyck Blank; Irina Fotina; Gregor Habl; Matthias Kretschmer; Gerd Lutters; Henning Salz; Kai Schubert; Daniela Wagner; Thomas G Wendt
Journal:  Radiat Oncol       Date:  2011-02-21       Impact factor: 3.481

Review 8.  Intensity-modulated radiation therapy, protons, and the risk of second cancers.

Authors:  Eric J Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-01       Impact factor: 7.038

9.  Comparative analysis of intensity modulation inverse planning modules of three commercial treatment planning systems applied to head and neck tumour model.

Authors:  Antonella Fogliata; Alessandra Bolsi; Luca Cozzi
Journal:  Radiother Oncol       Date:  2003-01       Impact factor: 6.280

10.  The influence of different IMRT techniques on the peripheral dose: a comparison between sMLM-IMRT and helical tomotherapy.

Authors:  Tilo Wiezorek; Andrea Schwahofer; Kai Schubert
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

View more
  1 in total

1.  mARC vs. IMRT radiotherapy of the prostate with flat and flattening-filter-free beam energies.

Authors:  Yvonne Dzierma; Katharina Bell; Jan Palm; Frank Nuesken; Norbert Licht; Christian Rübe
Journal:  Radiat Oncol       Date:  2014-11-26       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.